CryoCare Touch™ is a fully integrated, highly precise cryoablation treatment system featuring an intuitive touch screen interface that offers predictable therapy delivery with exceptional ease of technical operation.

Canada’s life sciences economy has shifted from a regional framework into a globally integrated powerhouse. Generating more than $13.7 billion in economic gross value added and sustaining upwards of 88,000 full-time equivalent positions, the Canadian medical device manufacturing infrastructure leverages deep academic research pipelines and targeted public-private partnerships.

The definition of a medical device is shifting from physical hardware toward clinical algorithms. As hospitals move toward decentralized care models, Software as a Medical Device (SaMD) driven by artificial intelligence and machine learning (ML) has evolved from an experimental concept into a mainstream clinical necessity. However, embedding adaptive intelligence into Canadian healthcare requires navigating unique regulatory frameworks and technical integration paths.

The Canadian medical device market is one of the largest in the world, valued at roughly US$9.8 billion and pacing toward US$13.5 billion by 2028. However, entering this lucrative space requires a thorough understanding of Health Canada’s regulatory ecosystem. Navigating these requirements demands a clear grasp of device classification, licensing paths, and recent legislative framework updates.

Selling medical devices to Canadian hospitals requires a distinct approach compared to navigating private, multi-payer corporate healthcare systems. Because Canadian healthcare operates under a publicly funded, single-payer structure managed at the provincial level, procurement is highly structured, strictly audited, and heavily centralized. Success in this market demands a strategic approach to institutional gatekeepers and a clear value proposition.